Navigation Links
Scientists explore promising new option for first line of attack in lymphoma
Date:2/25/2014

A study led by Manchester scientists has shown promising results for a new treatment approach in follicular lymphoma.

Follicular lymphoma is a type of non-Hodgkin's lymphoma a blood cancer - that usually develops slowly. The majority of patients are diagnosed when their disease is at an advanced stage.

Recent improvements in treatment have included the use of antibodies to specifically target the tumour cells and to stimulate the patient's own immune system to attack their tumour. The use of such antibodies has improved treatment response, but unfortunately most patients still relapse.

Radioimmunotherapy where a radioactive substance is attached to the antibody has been shown to be successful in treating patients who had previously relapsed.

Now a team involving researchers from The University of Manchester part of the Manchester Cancer Research Centre - has investigated the use of radioimmunotherapy treatment in newly diagnosed patients.

The study published in the Journal of Clinical Oncology, looked at the effect of delivering the treatment in two fractions or doses this approach is thought to improve the penetration of the drug within larger tumours and also helps reduce the side effects associated with a full dose treatment.

Professor Tim Illidge, who led the research, said: "This was the first study to look at giving two fractions of radioimmunotherapy as an initial treatment in follicular lymphoma. We wanted to assess its safety and effectiveness in a group of high-risk patients who conventionally have done less well."

The researchers found that that their treatment plan was feasible and safe, with very few side effects.

"We saw a high overall response rate, of 94.4%, and 50 of the 72 (69.4%) patients treated in the study achieved complete response meaning their symptoms disappeared. These results are encouraging, but we need further studies in larger numbers of patients to fully compare this treatment to the standard treatment of 6-8 cycles of chemotherapy," added Professor Illidge.


'/>"/>
Contact: Alison Barbuti
alison.barbuti@manchester.ac.uk
44-016-127-58383
University of Manchester
Source:Eurekalert

Related medicine news :

1. Tel Aviv University scientists honored for proposals in melanoma research
2. Scientists call for screening mammography every 2 years for most women
3. NIH scientists find mechanism that helps HIV evade antibodies, stabilize key proteins
4. Scientists develop powerful new animal model for metastatic prostate cancer
5. NIH scientists map gene changes driving tumors in common pediatric soft-tissue cancer
6. Scripps Florida scientists find regulator of amyloid plaque buildup in Alzheimers disease
7. NCCS scientists discover gene regulation is dependent on protein ANP32E
8. Scientists make your stomach turn bright green if you have an ulcer
9. Scientists reduce protein crystal damage, improve pharmaceutical development
10. It's All In The Climate: New Study from Research Scientists at Florida International University Predict
11. Surviving ovarian cancer: Rutgers scientists attack drug resistant cancer cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... San Francisco, CA (PRWEB) , ... October 12, ... ... and Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus ... sleep apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral ...
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... The American ... Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium ... 8. , In honor of Morris F. Collen, a pioneer in the field of ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... drug delivery system that we intend to develop to enable prevention of a ... lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in ... 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced ... 2017. , The annual award competition recognizes editorial and design excellence across a range ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... , Oct. 11, 2017  True Health, a ... amplified its effort during National Breast Cancer Awareness ... cancer risks. ... Oncology calculated that more than 10 million American ... mutations in BRCA1 or BRCA2 and have not had ...
(Date:10/10/2017)... , Oct. 10, 2017  NDS received FDA 510(k) clearance ... a medical-grade battery-powered display stand specifically designed for endoscopy environments. An ... technology into a clinical solution to support the improvement of patient ... Innovative Design ... Wireless Solution ...
(Date:10/7/2017)...   Provista, a proven leader in the ... purchasing power, today announced a new resource area on ... is the online home for case studies, articles ... news releases, slideshows and events. ... resources at their fingertips, viewers can also watch short ...
Breaking Medicine Technology: